Company profile
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of
- CEO
- —
- Headquarters
- New York, NY, United States
- Employees
- 3
- IPO date
- Jan 23, 2014
- Sector
- Technology
- Industry
- Computer Hardware